Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

2000, Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial, Lancet, 356, 2037, 10.1016/S0140-6736(00)03400-0 O'Shea, 2000, Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention, Am Heart J, 140, 834, 10.1067/mhj.2000.110458 Johnson, 2004, Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored, Biometrics, 60, 315, 10.1111/j.0006-341X.2004.00175.x 1994, Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, N Engl J Med, 330, 956, 10.1056/NEJM199404073301402 1997, Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention, Lancet, 349, 1422, 10.1016/S0140-6736(96)10172-0 1997, Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization, N Engl J Med, 336, 1689, 10.1056/NEJM199706123362401 1998, Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade, Lancet, 352, 87, 10.1016/S0140-6736(98)85010-1 Tcheng, 1994, Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty, Circulation, 90, 1757, 10.1161/01.CIR.90.4.1757 Harrington, 1995, Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention, Am J Cardiol, 76, 1222, 10.1016/S0002-9149(99)80345-2 Faulds, 1994, Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease, Drugs, 48, 583, 10.2165/00003495-199448040-00007 Kleiman, 1995, Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implication for inhibition of the internal pool of GPIIb/IIIa receptors, J Am Coll Cardiol, 26, 1665, 10.1016/0735-1097(95)00391-6 Jordan, 1996, Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans, 281 Phillips, 1997, Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate, Circulation, 96, 1488, 10.1161/01.CIR.96.5.1488